Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FADS1-shRNA
- Development stage
- Preclinical
- Lead developer
- Wayne State University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
FADS1-shRNA is a short hairpin RNA (shRNA) construct designed to silence the expression of Fatty acid desaturase 1 (FADS1). FADS1 is a key rate-limiting enzyme in the metabolism of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs). In preclinical studies involving renal cell carcinoma (RCC) cell lines, the use of FADS1-shRNA to knock down FADS1 expression resulted in significantly reduced cell proliferation, downregulation of DNA biosynthesis and cell division pathways, and altered purine metabolism. The anti-proliferative effect is potentially mediated through the inhibition of the MAPK pathway, specifically evidenced by reduced P38 phosphorylation. This research identifies FADS1 as a potential prognostic marker and therapeutic target in various cancers, particularly RCC.
- Other names
- FADS1 knockdown systemFADS-1 knockdown systemFADS 1 knockdown system
02
Targets
FADS1 (Fatty acid desaturase 1)
Beyond the preview
Go deeper on FADS1-shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FADS1-shRNA.